-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CctGSCmwq+MST7jZewSt/0kJHITyi+cprZbvISfrE8rGWQVMvf3jHPDKQIYeSR2w BUahGNOsqOPTXBcx2FPatA== 0000884847-07-000003.txt : 20070315 0000884847-07-000003.hdr.sgml : 20070315 20070315112339 ACCESSION NUMBER: 0000884847-07-000003 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070313 FILED AS OF DATE: 20070315 DATE AS OF CHANGE: 20070315 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MATRITECH INC/DE/ CENTRAL INDEX KEY: 0000884847 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 042985132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 330 NEVADA ST CITY: NEWTON STATE: MA ZIP: 02460 BUSINESS PHONE: 6179280820 MAIL ADDRESS: STREET 1: 330 NEVADA STREET CITY: NEWTON STATE: MA ZIP: 02460 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Musket David B CENTRAL INDEX KEY: 0001310611 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12128 FILM NUMBER: 07695490 BUSINESS ADDRESS: BUSINESS PHONE: (650) 614-4100 MAIL ADDRESS: STREET 1: C/O CONOR MEDSYSTEMS, INC. STREET 2: 1003 HAMILTON COURT CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 primary_doc.xml PRIMARY DOCUMENT X0202 4 2007-03-13 0 0000884847 MATRITECH INC/DE/ MZT 0001310611 Musket David B C/O MATRITECH, INC. 330 NEVADA STREET NEWTON MA 02460 1 0 1 0 Common Stock 2007-03-13 4 C 0 10993 A 65565 D Common Stock 2007-03-13 4 C 0 101785 A 1317001 I By various ProMed Funds Series A Convertible Promissory Notes 2007-03-13 4 C 0 5625 0 D Common Stock 10993 118125 D Series A Convertible Promissory Notes 2007-03-13 4 C 0 52083 0 D Common Stock 101785 1093750 I By various ProMed Funds Shares acquired as a result of Issuer's conversion of $5,625 of outstanding Series A Convertible Promissory Notes at a conversion price of $0.5117 per share. Shares acquired as a result of Issuer's conversion of $52,083 of outstanding Series A Convertible Promissory Notes at a conversion price of $0.5117 per share. By ProMed Partners, L.P., ProMed Partners II, L.P., ProMed Offshore Fund, Ltd. and ProMed Offshore Fund II, Ltd. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in the Funds, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or any other purpose. Disposition of $5,625 of outstanding Series A Convertible Promissory Notes as a result of the Issuer's conversion of Notes into shares of common stock at a price of $0.5117 per share. The reporting person still holds $118,125 of Series A Convertible Promissory Notes which are convertible by the reporting person at a price of $0.63 per share and which are convertible on specific installment payment dates at the option of the Issuer into shares of common stock at the lower of the conversion price, currently $0.63 per share, or 85% of the 10-day volume-weighted average trading price of the common stock. Disposition of $52,083 of outstanding Series A Convertible Promissory Notes as a result of the Issuer's conversion of Notes into shares of common stock at a price of $0.5117 per share. The various ProMed Funds still hold $1,093,750 of Series A Convertible Promissory Notes which are convertible by the ProMed Funds at a price of $0.63 per share and which are convertible on specific installment payment dates at the option of the Issuer into shares of common stock at the lower of the conversion price, currently $0.63 per share, or 85% of the 10-day volume-weighted average trading price of the common stock. Patricia Randall, under power of attorney 2007-03-15 -----END PRIVACY-ENHANCED MESSAGE-----